Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547890 | 0.80 | ESR1 (0.40) | ESR1ESR2 | |
| SCHEMBL19802021 | 0.80 | CYP19A1 (0.39) | CYP19A1ESR1ESR2 | |
| SCHEMBL25159075 | 0.77 | AAK1 (0.32) | ESR1ESR2 | |
| SCHEMBL24112018 | 0.76 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL25150684 | 0.76 | ESR1 (0.40) | ESR1ESR2 | |
| SCHEMBL22768844 | 0.74 | ESR1 (0.41) | ESR1ESR2 | |
| SCHEMBL20920347 | 0.70 | CYP19A1 (0.33) | CYP19A1ESR1ESR2 | |
| SCHEMBL21094546 | 0.70 | ESR1 (0.33) | CYP19A1ESR1ESR2 | |
| SCHEMBL19107508 | 0.69 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL2604908 | 0.69 | ESR1 (0.42) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | SMN1; SMN2, MUSK, MYOF | CYP19A1 4725/4885ESR1 4356/4885ESR2 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.